Friday, August 1, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

FDA Bucks Advisors to Approve Mitomycin for NMIBC

June 13, 2025
in Health News
Share on FacebookShare on Twitter


The FDA has approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

The intravesical mitomycin formulation is meant to be an alternative to the current standard of care for recurrent disease: Transurethral resection of bladder tumor (TURBT). The surgical procedure is usually done under general anesthesia, while Zusduri can be instilled by a catheter in a urologist’s office. Treatment is once a week for 6 weeks.

The approval came shortly after the FDA’s Oncologic Drugs Advisory Committee met to consider the agency’s concern that UroGen’s approval study — ENVISION — was a single-arm trial with no direct comparison to TURBT. The agency had concerns about comparative safety because TURBT’s side effects are generally limited to the day of the procedure, while Zusduri’s side effects span the full 6 weeks of administration. There were also concerns about comparative efficacy.

One panelist commented that without a randomized trial, “it’s very hard to determine the true benefit of this, and there is toxicity.” Plus, “this is a $140,000 treatment that might not change how many follow-up TURBTs you need after 3 months.”

The panel voted 5 to 4 that the risk/benefit of Zusduri wasn’t favorable based on the available data, but in the end, the FDA apparently decided it was.

The multicenter ENVISION trial included 240 adults who had recurred after TURBT and who had multiple tumors, a solitary tumor > 3 cm, and/or a recurrence within 1 year of TURBT. Patients in the trial were treated with 75 mg once a week for 6 consecutive weeks, the approved mitomycin dosage.

Among 223 evaluable patients, 78% had a complete response, meaning no detectable disease; 12 months after a complete response, 79% of patients remained recurrence free.

As for adverse events, 10% or more patients had increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.

Serious adverse events occurred in 12% of patients and included urinary retention (0.8%) and urethral stenosis (0.4%). One patient died of heart failure.

M. Alexander Otto is a physician assistant with a master’s degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape Medical News. Alex is also an MIT Knight Science Journalism fellow. Email: [email protected]



Source link : https://www.medscape.com/viewarticle/fda-bucks-advisors-approve-mitomycin-non-muscle-invasive-2025a1000fw5?src=rss

Author :

Publish date : 2025-06-13 11:51:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

What Role Does Diet Play in Managing Atopic Dermatitis?

Next Post

Add-On Simvastatin Shows No Benefit in Depression

Related Posts

Health News

States Sue Trump, Say Targeting of Hospitals Over Gender Care in Minors Is Unlawful

August 1, 2025
Health News

Time Your Meals, Tune Your Metabolism

August 1, 2025
Health News

Novel Eye Drops for Age-Related Blurry Vision Win FDA Approval

August 1, 2025
Health News

Bone Health in Duchenne Muscular Dystrophy

August 1, 2025
Health News

When Medicine Meets Philosophy: A New SEC Series

August 1, 2025
Health News

Alzheimer’s Benefits Continue With Donanemab for 3 Years, Long-Term Data Show

August 1, 2025
Load More

States Sue Trump, Say Targeting of Hospitals Over Gender Care in Minors Is Unlawful

August 1, 2025

Time Your Meals, Tune Your Metabolism

August 1, 2025

Novel Eye Drops for Age-Related Blurry Vision Win FDA Approval

August 1, 2025

Bone Health in Duchenne Muscular Dystrophy

August 1, 2025

When Medicine Meets Philosophy: A New SEC Series

August 1, 2025

Alzheimer’s Benefits Continue With Donanemab for 3 Years, Long-Term Data Show

August 1, 2025

Sweetener May Weaken Cancer Therapy; Hulk Hogan’s CLL; Top Cancer Hospitals

August 1, 2025

Ozzy Osbourne Shined a Light on Parkinson’s Stigma

August 1, 2025
Load More

Categories

Archives

August 2025
MTWTFSS
 123
45678910
11121314151617
18192021222324
25262728293031
« Jul    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version